Abstract
Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Current Pharmaceutical Design
Title:Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth
Volume: 24 Issue: 9
Author(s): Samir Gorasiya*, Juliet Mushi, Ryan Pekson, Sabesan Yoganathan and Sandra E. Reznik
Affiliation:
- Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John`s University, Queens, NY 11439,United States
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Abstract: Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Export Options
About this article
Cite this article as:
Gorasiya Samir *, Mushi Juliet , Pekson Ryan , Yoganathan Sabesan and Reznik E. Sandra , Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth, Current Pharmaceutical Design 2018; 24 (9) . https://dx.doi.org/10.2174/1381612824666180130121706
DOI https://dx.doi.org/10.2174/1381612824666180130121706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of the Neutrophil Proteome in Trauma Patients and Normal Controls
Protein & Peptide Letters Hepatitis B Vaccination in HIV-Infected Subjects
Current Molecular Pharmacology Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Molecular Concept of Diabetic Wound Healing: Effective Role of Herbal Remedies
Mini-Reviews in Medicinal Chemistry Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development
Current Medicinal Chemistry NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued) Effect of Extra Virgin Olive Oil and Table Olives on the ImmuneInflammatory Responses: Potential Clinical Applications
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Lysophospholipase D/Autotaxin in Lysophospholipid Biology
Current Enzyme Inhibition Recent Advances in Understanding of the Immunological Off-Target Effects of siRNA
Current Gene Therapy Newborn Screening through TREC, TREC/KREC System for Primary Immunodeficiency with limitation of TREC/KREC. Comprehensive Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry High-throughput Genotyping Methods for Pharmacogenomic Studies
Current Pharmacogenomics Retinoids in Cancer Chemoprevention
Current Cancer Drug Targets Pediatric Off-Label and Unlicensed Drug Use and Its Implications
Current Clinical Pharmacology The Role of Endostatin in Rheumatoid Arthritis
Current Rheumatology Reviews Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry